Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire
Abstract Background Rearrangements in the anaplastic lymphoma kinase (ALK) gene define a molecular subgroup of non-small-cell lung carcinoma (NSCLC) that should be treated with ALK-targeting tyrosine kinase inhibitors (TKIs). Objective This study aimed to portray the Portuguese reality about the dia...
Main Authors: | Ana Figueiredo, Ana Rodrigues, Carina Gaspar, Margarida Felizardo |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-10-01
|
Series: | Drugs - Real World Outcomes |
Online Access: | https://doi.org/10.1007/s40801-023-00393-z |
Similar Items
-
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
by: Mi Ran Yun, et al.
Published: (2019-12-01) -
Decreased Tertiary Lymphoid Structures in Lung Adenocarcinomas with ALK Rearrangements
by: Yi Zou, et al.
Published: (2022-10-01) -
PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK‐rearranged lung cancer
by: Sarang S. Talwelkar, et al.
Published: (2023-05-01) -
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
by: Yuki Katayama, et al.
Published: (2023-01-01) -
Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma.
by: Federica Zito Marino, et al.
Published: (2015-01-01)